Ionis Pharmaceuticals, Inc.
Methods for reducing LRRK2 expression
Last updated:
Abstract:
Provided herein are methods for decreasing LRRK2 mRNA expression. Such methods are useful to ameliorate LRRK2 associated diseases. Such LRRK2 associated diseases include Parkinson's Disease, including non-LRRK2 mediated Parkinson's Disease.
Status:
Grant
Type:
Utility
Filling date:
5 Jan 2017
Issue date:
2 Feb 2021